- Home
- BWLP vs MESO Comparison
BWLP vs MESO Comparison
Compare BWLP & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWLP
- MESO
- Stock Information
- Founded
- BWLP 1935
- MESO 2004
- Country
- BWLP Singapore
- MESO Australia
- Employees
- BWLP N/A
- MESO N/A
- Industry
- BWLP Marine Transportation
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BWLP Consumer Discretionary
- MESO Health Care
- Exchange
- BWLP Nasdaq
- MESO Nasdaq
- Market Cap
- BWLP 1.8B
- MESO 1.7B
- IPO Year
- BWLP N/A
- MESO N/A
- Fundamental
- Price
- BWLP $9.48
- MESO $10.72
- Analyst Decision
- BWLP
- MESO Buy
- Analyst Count
- BWLP 0
- MESO 4
- Target Price
- BWLP N/A
- MESO $18.00
- AVG Volume (30 Days)
- BWLP 492.7K
- MESO 240.4K
- Earning Date
- BWLP 05-27-2025
- MESO 02-26-2025
- Dividend Yield
- BWLP 25.48%
- MESO N/A
- EPS Growth
- BWLP N/A
- MESO N/A
- EPS
- BWLP 2.64
- MESO N/A
- Revenue
- BWLP $3,563,747,000.00
- MESO $5,670,000.00
- Revenue This Year
- BWLP N/A
- MESO $228.57
- Revenue Next Year
- BWLP $3.27
- MESO $356.77
- P/E Ratio
- BWLP $3.94
- MESO N/A
- Revenue Growth
- BWLP 20.91
- MESO N/A
- 52 Week Low
- BWLP $7.86
- MESO $4.60
- 52 Week High
- BWLP $22.31
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- BWLP 41.88
- MESO 38.38
- Support Level
- BWLP $9.15
- MESO $10.26
- Resistance Level
- BWLP $9.78
- MESO $11.33
- Average True Range (ATR)
- BWLP 0.46
- MESO 0.75
- MACD
- BWLP 0.00
- MESO 0.06
- Stochastic Oscillator
- BWLP 50.47
- MESO 37.37
About BWLP BW LPG Limited Common Shares
BW LPG Ltd is an LPG shipping. It uses pioneering technology to power its vessels with cleaner-burning liquefied petroleum gas (LPG) and invest in R&D to take towards a zero-carbon future. The company is organized into two main segments: The shipping segment and the product services segment which buy and sell liquid petroleum gas and deliver it to customers. It generates the majority of its revenue from the shipping segment.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.